We made history with safe and effective vaccines and we’ll keep working as long as there are people to protect, variants emerging, and research answers needed to keep us all safe. That means we still need you!
NIAID is conducting and supporting clinical trials evaluating therapies and vaccine candidates against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), as well as studies of people who have recovered from infection.
Featured COVID-19 Studies
Outpatient Treatment With Anti-Coronavirus Immunoglobulin (OTAC)
A research study testing an experimental COVID-19 treatment called anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG).
Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE)
A group of research studies to investigate drugs and treatment strategies for adults in the hospital with respiratory or lung infection, including COVID-19.
Estrategias y tratamientos para infecciones respiratorias y emergencias virales
Stopping Covid Progression With Early Protease Inhibitor Treatment (SCORPIO-HR ACTIV-2d)
A clinical research study looking at whether S-217622, an oral protease inhibitor, shortens the duration of COVID-19 symptoms and may reduce the risk of developing persistent COVID-related symptoms (long COVID).
Ongoing NIAID-supported COVID-19 Studies
Below is a selection of ongoing NIAID-supported studies. A frequently updated, comprehensive list of all COVID-19 clinical trials can be found on ClinicalTrials.gov.
Select from the options below based on the health category you fall under to find COVID-19 clinical study volunteer opportunities.
A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients
- Study Goal: The goal of this study is to evaluate the safety and efficacy of BIO 300 Oral Suspension to improve lung function in patients that were previously hospitalized with COVID-19 related pulmonary complications.
- Locations: New York, NY, Aurora, CO, Pearland, TX
- Sign Up to Volunteer: Visit A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 for eligibility and contact information.
- Official Study Title: BIO 300 Oral Suspension in Discharged COVID-19 Patients
COVID-19-Recovered Specimen Collection Study
- Study Goal: To further define and understand specific immune responses from blood samples donated by volunteers who are fully recovered from a confirmed COVID-19 infection.
- Locations: NIH Clinical Center in Bethesda, Maryland
- Sign Up to Volunteer: Visit the COVID-19-Recovered Specimen Collection Study page for eligibility and contact information.
- Official Study Title: Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies
Study of How COVID-19 Affects Blood Cells and the Immune System
- Study Goal: To study how SARS-CoV-2, the virus that causes COVID-19, affects the body, specifically how it affects blood cells and the immune system.
- Locations: Washington, DC Metro Area
- Sign Up to Volunteer: Visit the Study of How COVID-19 Affects Blood Cells and the Immune System page for eligibility and contact information
- Official Study Title: COVID-19–associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
Study of Long-Term Medical Problems and Long-Term Immunity After COVID-19 Recovery
- Study Goal: To study the long-term medical problems experienced by people who recover from COVID-19 and whether people who recover develop long-term immunity to SARS-CoV-2, the virus that causes COVID-19.
- Locations: The NIH in Bethesda, Maryland
- Sign Up to Volunteer: Visit the Study of Long-Term Medical Problems and Long-Term Immunity After COVID-19 Recovery page for eligibility and contact information
- Official Study Title: Longitudinal Study of COVID-19 Sequelae and Immunity (RECON_19)
These studies are seeking volunteers who have had a confirmed diagnostic test for COVID-19 but are not sick enough to need hospitalization.
ACTIV-2d/A5407
- Study Goal: A clinical research study looking at whether S-217622, an oral protease inhibitor, shortens the duration of COVID-19 symptoms and may reduce the risk of developing persistent COVID-related symptoms (long COVID).
- Locations: 243 study sites in North America, South America, Europe, Africa, and Asia.
- Sign Up to Volunteer: Complete the screening questionnaire
- Official Study Title: A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19
Outpatient Treatment With Anti-Coronavirus Immunoglobulin (OTAC)
- Study Goal: To test an experimental COVID-19 treatment called anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG).
- Locations: Visit ClincialTrials.gov to find an OTAC trial site near you.
- Sign Up to Volunteer: Email dcrcombatcovidhelp@mail.nih.gov
- Official Study Title: An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
Study of How COVID-19 Affects Blood Cells and the Immune System
- Study Goal: To learn how SARS-CoV-2, the virus that causes COVID-19, affects the body—specifically how it affects blood cells and the immune system.
- Locations: Washington, DC, Metro Area
- Sign Up to Volunteer: Visit our Study of How COVID-19 Affects Blood Cells and the Immune System page for eligibility and contact information.
- Official Study Title: COVID-19-Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
These studies are occurring in specific hospitals and seeking volunteers with severe COVID-19. Volunteers will typically be connected to the studies through their medical care providers.
A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients
- Study Goal: The goal of this study is to evaluate the safety and efficacy of BIO 300 Oral Suspension to improve lung function in patients that are ready to be discharged from the hospital with COVID-19 related pulmonary complications.
- Locations: New York, NY, Aurora, CO, Pearland, TX
- Sign Up to Volunteer: Visit A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 for eligibility and contact information.
- Official Study Title: BIO 300 Oral Suspension in Discharged COVID-19 Patients
Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE) Shionogi S-217622 Study
- Study Goal:The goal of this study is to determine if S-217622 is safe and if it will help adults in the hospital with COVID-19 get better and go home faster, when given in addition to standard treatments.
- Locations: Visit ClinicalTrials.gov to find contact information for a nearby study location.
- Sign Up to Volunteer: Send an email to the email address shown on ClinicalTrials.gov for your nearest study location, or email sitereg@insight-trials.org for more information about joining the STRIVE study.
- Official Study Title: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (S-217622)
Study of How COVID-19 Affects Blood Cells and the Immune System
- Study Goal: To study how SARS-CoV-2, the virus that causes COVID-19, affects the body—specifically how it affects blood cells and the immune system.
- Locations: Washington, DC, Metro Area
- Sign Up to Volunteer: Visit our Study of How COVID-19 Affects Blood Cells and the Immune System page for eligibility and contact information.
- Official Study Title: COVID-19-Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)